Antonio Palumbo

Antonio Palumbo

UNVERIFIED PROFILE

Are you Antonio Palumbo?   Register this Author

Register author
Antonio Palumbo

Antonio Palumbo

Publications by authors named "Antonio Palumbo"

Are you Antonio Palumbo?   Register this Author

100Publications

4728Reads

39Profile Views

Curative and Prophylactic Surgery of Young-onset Colorectal Cancer in Inherited Syndromes: A 15-Year Monocentric Retrospective Experience.

Anticancer Res 2019 Jun;39(6):3131-3136

Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sapienza University, St. Andrea Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13449DOI Listing
June 2019

Potential Therapeutic Effects of Underground Parts of on Benign Prostatic Hyperplasia.

Evid Based Complement Alternat Med 2019 2;2019:6340757. Epub 2019 Jan 2.

Instituto de Pesquisas de Produtos Naturais, Universidade Federal do Rio de Janeiro, 21941-902 Rio de Janeiro, RJ, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/6340757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334319PMC
January 2019

Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer.

World J Urol 2018 Dec 6;36(12):2009-2019. Epub 2018 Jul 6.

Laboratório de Interações Celulares, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Cidade Universitária-Ilha do Fundão, Rio de Janeiro, CEP 21941-902, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2392-6DOI Listing
December 2018

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.

Leukemia 2018 08 30;32(8):1803-1807. Epub 2018 Jan 30.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0024-1DOI Listing
August 2018

Stem Cell Transplantation in Multiple Myeloma.

Curr Cancer Drug Targets 2017 ;17(9):769-781

Division of Hematology, University of Torino, Via Genova 3, 10126 Torino. Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009616666160920090236DOI Listing
June 2018

HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas.

Histopathology 2018 Jun 9;72(7):1102-1114. Epub 2018 Mar 9.

Programa de Carcinogênese Molecular, Instituto Nacional de Câncer - INCA, Rio de Janeiro, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13456DOI Listing
June 2018

UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1.

Genes (Basel) 2018 Mar 29;9(4). Epub 2018 Mar 29.

Programa de Carcinogênese Molecular, Instituto Nacional de Câncer-INCA, Rua Andre Cavalcanti 37, Rio de Janeiro 20231-050, RJ, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/genes9040188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924530PMC
March 2018

Case report: skin injury after contact with a red spine starfish, Protoreaster lincki.

Contact Dermatitis 2018 Jan;78(1):95-96

Department of Pathology and Pathology Research Unit, St Andrea University Hospital, 00189 Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.12865DOI Listing
January 2018

Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients.

Surgeon 2017 Dec 17;15(6):329-335. Epub 2017 Jun 17.

Department of General Surgery, University of Rome, "La Sapienza", Sant'Andrea Hospital, Via di Grottarossa, 1035-1039, 00189, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.surge.2017.05.007DOI Listing
December 2017

Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.

Cell Biol Int 2017 Nov 18;41(11):1239-1245. Epub 2017 May 18.

Programa de Pesquisa em Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, CEP: 21941-902, Rio de Janeiro, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbin.10785DOI Listing
November 2017

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

J Clin Oncol 2017 Oct 25;35(29):3279-3289. Epub 2017 Jul 25.

Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6679DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652871PMC
October 2017

Plasma cell leukemia: update on biology and therapy.

Leuk Lymphoma 2017 07 6;58(7):1538-1547. Epub 2016 Nov 6.

a Myeloma Unit, Division of Hematology , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1250263DOI Listing
July 2017

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

Cancer Treat Res 2016;169:123-143

Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-40320-5_8
Publisher Site
http://dx.doi.org/10.1007/978-3-319-40320-5_8DOI Listing
June 2017

Novel investigational drugs active as single agents in multiple myeloma.

Expert Opin Investig Drugs 2017 Jun 8;26(6):699-711. Epub 2017 May 8.

a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1324571DOI Listing
June 2017

Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.

Leuk Lymphoma 2016 23;57(3):537-56. Epub 2015 Dec 23.

a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.3109/10428194.2015.1
Publisher Site
http://dx.doi.org/10.3109/10428194.2015.1102245DOI Listing
December 2016

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?

Expert Opin Drug Saf 2016 Oct 5;15(10):1295-300. Epub 2016 Jul 5.

a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1201061DOI Listing
October 2016

Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach.

J Clin Oncol 2016 Oct;34(30):3600-3604

University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.6113DOI Listing
October 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Aug;375(8):754-66

From the Department of Hematology, University of Turin, Turin, Italy (A.P.); the Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville (A.C.-K.); Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen (K.W.), and University Medical Center of the Johannes Gutenberg-University, Third Department of Medicine, Mainz (M.M.) - both in Germany; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the Department of Hematology and Stem Cell Transplantation, St. László Hospital, Semmelweis University, Budapest, Hungary (T.M.); Ankara University, Department of Hematology, Ankara, Turkey (M.B.); Clinical Department of Hematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic (I.S.); Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo (V.H.); University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain (M.V.M.); Weill Cornell Medical College, New York (T.M.M.); Janssen Research and Development, Spring House, PA (M.Q., X.Q., T.A.); Janssen Research and Development, Raritan, NJ (J.S., H.A.); Janssen Research and Development, Beerse, Belgium (W.D.); Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia (A.S.); and the Department of Hematology, Erasmus MC, Rotterdam, the Netherlands (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1606038DOI Listing
August 2016

New pharmacotherapy options for multiple myeloma.

Expert Opin Pharmacother 2016 18;17(2):181-92. Epub 2015 Dec 18.

a Myeloma Unit , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2016.1115016DOI Listing
June 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0044DOI Listing
May 2016

Moving Toward a Tailored Therapy in Multiple Myeloma.

J Oncol Pract 2016 Apr;12(4):293-4

University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.011627DOI Listing
April 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016

Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply.

Lancet Oncol 2016 04 29;17(4):e126. Epub 2016 Mar 29.

Amgen, South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)00145-5DOI Listing
April 2016

MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?

Expert Rev Mol Diagn 2015 12;15(7):881-93. Epub 2015 May 12.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737159.2015.1046436DOI Listing
March 2016

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

Blood 2016 Feb 2;127(6):681-95. Epub 2015 Dec 2.

Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-646810DOI Listing
February 2016

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.

Cytometry B Clin Cytom 2016 Jan 23;90(1):81-90. Epub 2015 Sep 23.

Divisione Universitaria Di Ematologia, AOU Città Della Salute E Della Scienza Di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21279DOI Listing
January 2016

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.

Expert Rev Hematol 2016 Jan;9(1):91-105

c Department of Haematology , University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2016.1119041DOI Listing
January 2016

Clinical characteristics of patients with relapsed multiple myeloma.

Cancer Treat Rev 2015 Dec 31;41(10):827-35. Epub 2015 Jul 31.

Department of Hematology, University of Torino, Via Genova 3, 10126 Torino, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2015.07.005DOI Listing
December 2015

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494PMC
December 2015

Immunotherapy: the next step in the treatment of myeloma.

Authors:
Antonio Palumbo

Lancet Haematol 2015 Dec 16;2(12):e504-5. Epub 2015 Nov 16.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino 10126, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026150022
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(15)00226-4DOI Listing
December 2015

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

J Mol Diagn 2015 Nov 28;17(6):652-60. Epub 2015 Aug 28.

Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy; Hematology Division, A.O.S. Antonio, Biagio and Cesare Arrigo, Alessandria, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2015.05.007DOI Listing
November 2015

How I treat fragile myeloma patients.

Blood 2015 Nov 31;126(19):2179-85. Epub 2015 Aug 31.

Myeloma Unit, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-612960DOI Listing
November 2015

Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.

Oncoimmunology 2015 Nov 26;4(11):e1047580. Epub 2015 May 26.

Laboratorio di Ematologia Oncologica; Centro di Ricerca in Medicina Sperimentale (CeRMS); Torino, Italy ; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute; Università degli Studi di Torino ; Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1047580DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589055PMC
November 2015

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.

PLoS One 2015 28;10(1):e0116966. Epub 2015 Jan 28.

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; European Myeloma Network Board, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116966PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309532PMC
October 2015

Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?

Biol Blood Marrow Transplant 2015 Oct 8;21(10):1705-6. Epub 2015 Aug 8.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.08.005DOI Listing
October 2015

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

J Clin Oncol 2015 Oct 17;33(30):3459-66. Epub 2015 Aug 17.

Antonio Palumbo, Francesca Gay, Federica Cavallo, Alessandra Larocca, Francesca Donato, Chiara Cerrato, Luana Boccadifuoco, and Mario Boccadoro, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Giulia Benevolo, S.C. Ematologia A.O. Città della Salute e della Scienza di Torino; Tommasina Guglielmelli, University of Turin and San Luigi Hospital; Giovannino Ciccone, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and CPO Piemonte, Torino; Francesco Di Raimondo, Ospedale Ferrarotto, Azienda Policlinico-OVE, University of Catania, Catania; Maria T. Petrucci, Sapienza University of Rome; Tommaso Caravita, Ematologia Ospedale S. Eugenio, Rome; Sara Pezzatti, Azienda Ospedaliera San Gerardo, Monza; Francesca Patriarca, DISM, University Hospital, Udine; Chiara Nozzoli, AOU Careggi, Florence; Donatella Vincelli, A.O "Bianchi-Melacrino-Morelli," Reggio Calabria; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Referral Cancer Center of Basilicata, Rionero in Vulture; Paolo Corradini, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano; Michele Cavo, Institute of Hematology and Medical Oncology "Seràgnoli," Bologna University School of Medicine S. Orsola's University Hospital, Bologna, Italy; Izhar Hardan, Meir Medical Center, Kfar-Saba; Arnon Nagler, Tel Aviv University, Chaim Sheba Medical Center, Tel-Hashomer, Israel; Roman Hajek, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic; Michel Delforge, University Hospital Leuven, Leuven, Belgium; Zhinuan Yu and Christian Jacques, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens, School of Medicine, Alexandra Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.2466DOI Listing
October 2015

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

J Clin Oncol 2015 Sep 3;33(26):2863-9. Epub 2015 Aug 3.

Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome, Rome; Elena Zamagni and Michele Cavo, Istituto di Ematologia Seragnoli, Università di Bologna, Bologna, Italy; Hervé Avet-Loiseau and Michel Attal, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse; Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, Centre Hospitalier Regionale et Universitaire Lille, Lille; Philippe Moreau, University Hospital Hotel-Dieu, Nantes, France; Henk M. Lokhorst, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC, Rotterdam, the Netherlands; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Laura Rosinol, Hospital Clínic, Institut Clínic d'Investigacions Biomèdiques Ausgust Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jésus San Miguel, Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, IDISNA, Pamplona, Spain; Paul Richardson and Kenneth C. Anderson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Shaji Kumar and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA; Robert Z. Orlowski, The University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX; Gareth Morgan, Myeloma Institutes for Research Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Brian G.M. Durie, Cedars-Sinai Comprehensive Canc

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/03/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.2267
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.2267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846284PMC
September 2015

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

N Engl J Med 2015 Sep 26;373(13):1207-19. Epub 2015 Aug 26.

From the Department of Hematology, University Medical Center Utrecht, Utrecht (H.M.L., M.C.M., N.W.C.J.D.), and the Department of Hematology, VU University Medical Center, Amsterdam (H.M.L., N.W.C.J.D.) - both in the Netherlands; Vejle Hospital and University of Southern Denmark, Vejle (T.P., J.K.), and Rigshospitalet and University of Copenhagen (P.G., U.L.) and Genmab (N.L., S.L., L.B., N.B.), Copenhagen - all in Denmark; Dana-Farber Cancer Institute, Harvard Medical School, Boston (J.P.L., P.G.R.); Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.), and Skåne University Hospital and Lund University, Lund (M.H.) - all in Sweden; Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy (A.P.); Janssen Research and Development, Spring House, PA (T.A., C.M.U., A.K.S.); and Janssen Research and Development, Raritan, NJ (I.K., J.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506348DOI Listing
September 2015

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

N Engl J Med 2015 Aug 2;373(7):621-31. Epub 2015 Jun 2.

From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.L.); National and Kapodistrian University of Athens, Athens (M.D.); A.O.U. San Giovanni Battista di Torino-Ospedale Molinette, Turin, Italy (A.P.); QEII Health Science Center and Dalhousie University, Halifax, NS (D.W.), Cross Cancer Institute and University of Alberta, Edmonton (A.B.), and Princess Margaret Cancer Centre, Toronto (D.R.) - all in Canada; Silesian Medical University, Katowice (S.G.), and Medical University of Lublin, Lublin (A.W.-C.) - both in Poland; Charles University Hospital, Prague, Czech Republic (I.S.); University Hospital, Nantes, France (P.M.); Complejo Asistencial Universitario de Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Ramat Aviv - both in Israel (H.M.); Ankara University, Ankara, Turkey (M.B.); Alfred Health-Monash University, Melbourne, VIC, Australia (A. Spencer); Barts and the London NHS Trust, London (H.O.); University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); Kyoto Prefectural University of Medicine, Kyoto (M.T.), and Nishigunma National Hospital, Shibukawa (M.M.) - both in Japan; Universitätsklinikum der Technische Universität, Dresden (C.R.), and Universitätsklinikum Würzburg, Würzburg (H.E.) - both in Germany; Zeikenhuis Netwerk Antwerpen (ZNA) Stuivenberg, Antwerp, Belgium (K.L.W.); AbbVie Biotherapeutics, Redwood City, CA (A. Singhal); Bristol-Myers Squibb, Princeton, NJ (J.K.), Wallingford, CT (E.B.), and Braine-l'Alleud, Belgium (V.P.); and Dana-Farber Cancer Institute, Boston (K.C.A., P.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1505654DOI Listing
August 2015

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.

Expert Rev Hematol 2015 Aug 12;8(4):481-91. Epub 2015 Jun 12.

Myeloma Unit, Division of Haematology, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1053866DOI Listing
August 2015

Genetic instability in the tumor microenvironment: a new look at an old neighbor.

Mol Cancer 2015 Jul 31;14:145. Epub 2015 Jul 31.

Laboratório de Interações Celulares, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Prédio de Ciências da Saúde - Cidade Universitária, Ilha do Fundão, A. Carlos Chagas, 373 - bloco F, sala 26, 21941-902, Rio de Janeiro, RJ, Brasil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-015-0409-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521350PMC
July 2015

Multiple myeloma: is a shift toward continuous therapy needed to move forward?

Expert Rev Hematol 2015 Jun 12;8(3):253-6. Epub 2015 Jan 12.

Unit of Hematology, 'S. Luigi Gonzaga' Hospital, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1001360DOI Listing
June 2015

Treatment of relapsed multiple myeloma.

N Engl J Med 2015 04;372(18):1774-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1501348DOI Listing
April 2015

The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.

Drugs 2015 Mar;75(4):367-75

Myeloma Unit, Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Via Genova 3, 10126, Torino, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s40265-015-0367
Web Search
http://link.springer.com/10.1007/s40265-015-0367-0
Publisher Site
http://dx.doi.org/10.1007/s40265-015-0367-0DOI Listing
March 2015

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

J Clin Oncol 2015 Feb 20;33(6):657-64. Epub 2015 Jan 20.

Meletios A. Dimopoulos and Evangelos Terpos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; Jens Hillengass and Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany; Saad Usmani, Carolinas Healthcare System, Charlotte, NC; Elena Zamagni and Michele Cavo, Bologna University School of Medicine, Bologna; Antonio Palumbo, S. Giovanni Battista Hospital, University of Turin, Turin, Italy; Suzanne Lentzsch, Columbia University College of Physicians and Surgeons, New York, NY; Faith E. Davies, Institute of Cancer Research, Sutton, United Kingdom; Noopur Raje, Massachusetts General Hospital Cancer Center; Kenneth Anderson, Dana-Farber Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Orhan Sezer, Memorial Sisli Hospital, Istanbul, Turkey; Sonja Zweegman, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, the Netherlands; Jatin Shah, MD Anderson Cancer Center, Houston, TX; Ashraf Badros, University of Maryland Medical Center, Baltimore, MD; Kazuyuki Shimizu, Tokai Central Hospital, Kakamigahara, Japan; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; Chor-Sang Chim, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region; Jian Hou, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Artur Jurczyszyn, University Hospital, Krakow, Poland; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Bart Barlogie, University of Arkansas for Medical Sciences, Little Rock, AR; G. David Roodman, Indiana University School of Medicine, Indianapolis, IN; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; and Brian G.M. Durie, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.9961DOI Listing
February 2015